AOD-9604 vs Tesamorelin.
AOD-9604 vs Tesamorelin: comparing mechanisms, efficacy, dosing and side effects for visceral fat loss and body composition research.
Quick Verdict
Tesamorelin drives stronger fat loss via GH receptor activation (FDA-approved for lipodystrophy). AOD-9604 offers targeted lipolysis without GH receptor binding — ideal for subjects who need fat loss without GH-axis concerns.
Side-by-Side Analysis
| Dimension | AOD-9604 | Tesamorelin |
|---|---|---|
| Mechanism | Mimics GH fat-burning domain. | Stimulates GH for fat metabolism. |
| Primary Benefits | Fat loss without GH side effects | Visceral fat reduction, body recomposition |
| Typical Dose | 300–300mcg | 1000–1000mcg |
| Route | SubQ | SubQ |
| Frequency | 7x/wk | 7x/week |
| Half-Life | 1 hours | 0.43 hours |
| FDA Status | Research Only | Approved |
| Evidence Grade | preclinical | very-strong |
| Key Studies | 18+ indexed | 20+ indexed |
| Lowest Price | $49.99 / 5mg via Amino Club | $69.99 / 10mg via Amino Club |
Which one should you choose?
Who Should Choose AOD-9604?
Choose AOD-9604 if you:
- Want direct lipolysis without GH receptor stimulation
- Are sensitive to blood sugar disruption from GH elevation
- Are researching fat loss as an add-on to an existing GH protocol
- Need a very mild, well-tolerated fat loss agent
Who Should Choose Tesamorelin?
Choose Tesamorelin if you:
- Want the most aggressive visceral fat reduction available
- Are comfortable with the full GHRH mechanism and GH stimulation
- Are researching lipodystrophy or metabolic syndrome specifically
- Want an FDA-approved mechanism with clinical trial data
Can you stack AOD-9604 + Tesamorelin?
These can be stacked carefully. AOD-9604 acts peripherally on fat cells; Tesamorelin acts centrally via the pituitary. The combination may produce additive fat loss effects. However, researchers should monitor IGF-1 and blood glucose when stacking any GH-axis peptide.
Vendor Pricing
· Affiliate links · Prices verified 2026AOD-9604
2 vendorsAffiliate disclosure: PeptiDex may earn a commission from purchases via vendor links at no extra cost to you. See our methodology.
Frequently Asked Questions
No — this is AOD-9604's key advantage. It does not bind the GH receptor and does not raise IGF-1 or affect blood sugar, unlike full-length GH or GHRH analogs like Tesamorelin.
Related Comparisons
Deep Dive Profiles
Research Tools
Research Use Only — Not Medical Advice
This comparison is provided for educational and research purposes only. It does not constitute medical, prescribing, or treatment advice. Clinical data cited here is sourced from published peer-reviewed trials and FDA labels. Consult a qualified healthcare professional before making any decisions about medications or research compounds. PeptiDex is an informational resource and does not sell pharmaceutical products.